Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Contineum Therapeutics, Inc. Class A ( (CTNM) ).
Contineum Therapeutics amended its existing at-the-market equity program with Leerink Partners on March 5, 2026, raising the total capacity for Class A common stock issuance to $100 million, excluding amounts already sold, while committing not to sell shares under the facility until after a lock-up expires on March 11, 2026. The same day, the company reported fourth-quarter 2025 results, highlighting a $262.9 million cash position expected to fund operations through mid-2029, initiation of patient dosing in its global Phase 2 PROPEL-IPF trial of PIPE-791 in idiopathic pulmonary fibrosis, progress in chronic pain and depression studies with partners including Johnson & Johnson, and a modest year-over-year increase in quarterly net loss to $15.2 million despite disciplined spending on its expanding clinical pipeline.
The company also outlined that PROPEL-IPF, a 26-week, randomized, double-blind, placebo-controlled Phase 2 trial, will evaluate the efficacy, safety and tolerability of once-daily oral PIPE-791 in about 324 patients with idiopathic pulmonary fibrosis. In parallel, Contineum is advancing an exploratory Phase 1b chronic pain trial of PIPE-791, with topline data expected in the second quarter of 2026, while Johnson & Johnson continues a Phase 2 Moonlight-1 study of PIPE-307 in major depressive disorder, underscoring Contineum’s strategy to prioritize its lead IPF program while leveraging partnerships to broaden its NI&I pipeline.
The most recent analyst rating on (CTNM) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Contineum Therapeutics, Inc. Class A stock, see the CTNM Stock Forecast page.
Spark’s Take on CTNM Stock
According to Spark, TipRanks’ AI Analyst, CTNM is a Neutral.
The score is held back primarily by weak financial performance (no TTM revenue, large losses, and worsening cash burn) and a negative Phase 2 efficacy readout. These are partly offset by a supportive technical setup (above key moving averages with positive MACD) and a balance sheet with low debt and solid equity providing financial flexibility.
To see Spark’s full report on CTNM stock, click here.
More about Contineum Therapeutics, Inc. Class A
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on novel, oral small molecule therapies for neuroscience, inflammation and immunology indications with significant unmet need. Its lead candidates include PIPE-791, an LPA1 receptor antagonist in development for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being advanced for relapsing-remitting multiple sclerosis and major depressive disorder.
Average Trading Volume: 257,303
Technical Sentiment Signal: Buy
Current Market Cap: $515.1M
Find detailed analytics on CTNM stock on TipRanks’ Stock Analysis page.